ASCO: Sarclisa 1st anti-CD38 to improve progression-free survival in combo for multiple myeloma

 

• Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd reduced the risk of recurrence or death by 40% versus VRd followed by Rd in the investigational use for transplant-ineligible newly diagnosed multiple myeloma patients
• Key primary endpoint of progression-free survival met, demonstrating Sarclisa's potential as a first-in-class combination to address gaps in care for newly diagnosed transplant-ineligible patients
• Full data simultaneously published in NEJM and formed the basis of regulatory submissions

https://www.sanofi.com/en/media-room/press-releases/2024/2024-06-03-20-15-00-2892607